Dr Wiebke Rösler speaks to ecancer about how prophylactic tocilizumab prior to infusion of anti-CD19 CAR-T cells may reduce the incidence of toxicity in older lymphoma patients.

The study examines CAR T-cell therapy's effectiveness in older patients with relapsed lymphoma, addressing treatment efficacy and toxicity.

It stresses the need for more data on patient outcomes and highlights the potential cost-effectiveness of tocilizumab in reducing ICU needs.

Future research will focus on larger patient groups and geriatric assessments to better predict toxicities and define eligibility criteria, ensuring relevant endpoints for this demographic.